Haifaa Abdulhaq, MD
Professor
Medicine - Fresno
School of Medicine

Clinical Professor, UCSF

Haifaa Abdulhaq, M.D. is Clinical Professor in Hematology and Oncology, UCSF and she is the director of hematology at UCSF Fresno and the director of Hematology/Oncology fellowship program at UCSF Fresno. She is board certified in hematology and medical oncology with expertise in Malignant Hematology including Lymphoproliferative neoplasms, Myeloproliferative neoplasms, Acute Leukemia, Multiple Myeloma and interest in Stem Cell transplantation. Dr. Abdulhaq completed her residency in internal medicine and fellowship in hematology & oncology at Western Pennsylvania Hospital and Allegheny General Hospital in Pittsburgh, Pennsylvania. She is a member of The American Society of Hematology, the American Board of Internal Medicine, the American Society of Clinical Oncology and the American Society of Blood and Bone Marrow Transplantation. Dr. Abdulhaq is a board member of the Leukemia and Lymphoma Society, Central California Chapter and she also serves as the chair of Cancer Committee at Community Medical Centers.

Dr. Abdulhaq has special interest in medical education. She is a recipient of Henry Kaiser Award for Excellence in teaching at UCSF . She is also interested in clinical research and serves as the principal investigator on many clinical trials in malignant hematology.

• Realmind: A Prospective and Retrospective Study to Characterize Real-World Use of Tafasitamab Plus Lenalidomide in US Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, with a Focus on Patients from Minority Groups.
  Blood 2023 Elizabeth A. Brem, John M. Burke, Mirko Vukcevic, Pia Kloepfer, Kimberly Saverno, Haifaa Abdulhaq, Andrew M Evens, Pierluigi Porcu, Mazyar Shadman, Christopher R. Flowers
• Trends in Diffuse Large B-Cell Lymphoma Mortality in the United States: A Comprehensive Review from 2000 to 2020.
  Blood 2023 Abdul Rahman Al Armashi, Anas Al Zubaidi, Omar Mahmood, Marisa Thierheimer, Akram Alkrekshi, Haifaa Abdulhaq
• Trial in Progress: A Phase I/II Study of Tafasitamab Plus Lenalidomide in Patients with Relapsed CNS Lymphoma.
  Blood 2023 Michael P Randall, Andreas Rauschecker, Liam Gima-Lange, Jenai Wilmoth, Lingjing Chen, Ming Lu, Huimin Geng, Haifaa Abdulhaq, James L. Rubenstein
• Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study.
  European journal of haematology 2023 Schjesvold FH, Ludwig H, Mateos MV, Larocca A, Abdulhaq H, Norin S, Thuresson M, Bakker NA, Richardson PG, Sonneveld P
• Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context.
  OncoTargets and therapy 2023 Abdulhaq H, Hwang A, Mahmood O
• Impact of Thiotepa-Based Autologous Hematopoietic Cell Transplantation in Primary Central Nervous System Lymphoma in First Complete Remission: A University of California Hematologic Malignancies Consortium Retrospective Analysis.
  Clinical lymphoma, myeloma & leukemia 2023 Othman T, Quan MA, Zhang S, Gaut D, Young PA, Mahmood O, Abdulhaq H, Shieh K, Reid J, Brem EA, Hariharan N, Heyman B, Tuscano J
• Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies.
  Clinical lymphoma, myeloma & leukemia 2023 Sonneveld P, Richardson PG, Ludwig H, Dimopoulos MA, Schjesvold FH, Hájek R, Abdulhaq H, Thuresson M, Norin S, Bakker NA, Mateos MV
• Disparities in Somatic Mutations and Outcomes in Primary Central Nervous System Lymphoma Comparing Patients of Hispanic and Non-Hispanic Ethnicity
  2022 Haifaa Abdulhaq, Omar Mahmood, Calvin Kuan Jung Chen, Azra Borogovac, Matthew Wieduwilt, Anand Annan, Yueqi Yan, Maher Albitar
• A Phase II Trial of the Combination of Obinutuzumab, Venetoclax, and Ibrutinib in Patients with Previously Untreated Follicular Lymphoma.
  Blood 2022 Tamer Othman, Aaron S Rosenberg, John Timmerman, Benjamin Heyman, Haifaa Abdulhaq, Joseph M Tuscano
• Avoiding Daratumumab Interference with Blood Typing.
  Blood 2022 Charity A Huang, Fouad Boulbol, Sundeep Bekal, Seema Policepatil, Haifaa Abdulhaq, Sani Bukari
• Characteristics and Outcomes of Multiple Myeloma in Hispanic Versus Non-Hispanic Patients in Central California.
  Blood 2022 Andrew Hwang, Daniel Park, Jason Doornenbal, Inderpreet Bal, Sani Bukari, Yueqi Yan, Haifaa Abdulhaq
• Disparities in Somatic Mutations and Outcomes in Primary Central Nervous System Lymphoma Comparing Patients of Hispanic and Non-Hispanic Ethnicity.
  Blood 2022 Haifaa Abdulhaq, Omar Mahmood, Calvin Kuan Jung Chen, Azra Borogovac, Matthew Wieduwilt, Anand Annan, Yueqi Yan, Maher Albitar
• Impact of Timing of Autologous Hematopoietic Cell Transplantation in Primary Central Nervous System Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis.
  Blood 2022 Tamer Othman, Michelle A. Quan, Shiliang Zhang, Daria Gaut, Patricia A. Young, Haifaa Abdulhaq, Kevin Shieh, Jack Reid, Elizabeth A. Brem, Benjamin Heyman, Joseph Tuscano
• OCEAN (OP-103): Melflufen/Dexamethasone Compared Wth Pomalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - Subgroup Analysis in Patients Refractory to Prior Alkylators.
  Blood 2022 Fredrik Schjesvold, Heinz Ludwig, María-Victoria Mateos, Haifaa Abdulhaq, Stefan Norin, Marcus Thuresson, Nicolaas A. Bakker, Paul G. Richardson, Pieter Sonneveld
• ABCL-051 realMIND: A Prospective, Multicenter, Observational Study of Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Starting Second/Third-Line Therapy and Not Receiving a Stem Cell Transplant.
  Clinical Lymphoma Myeloma & Leukemia 2022 Christopher R. Flowers, John M. Burke, Mirko Vukcevic, Susan Snodgrass, Kim Saverno, Mary Ann A. Lumiqued, Haifaa Abdulhaq, Elizabeth Brem, Andrew Evens, Umar Farooq, Pierluigi Porcu, Mazyar Shadman
• Poster: ABCL-051 realMIND: A Prospective, Multicenter, Observational Study of Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Starting Second/Third-Line Therapy and Not Receiving a Stem Cell Transplant.
  Clinical Lymphoma Myeloma & Leukemia 2022 Christopher R. Flowers, John M. Burke, Mirko Vukcevic, Susan Snodgrass, Kim Saverno, Mary Ann A. Lumiqued, Haifaa Abdulhaq, Elizabeth Brem, Andrew Evens, Umar Farooq, Pierluigi Porcu, Mazyar Shadman
• Evaluation of pulmonary toxicities in lymphoma patients receiving brentuximab vedotin.
  Leukemia & lymphoma 2022 Guan T, Lo M, Young R, Ai W, Boulbol F, Mouanoutoua H, Chu R, Andreadis C, Kaplan L, Abdulhaq H, Fakhri B
• R-CHOP Vs DA-EPOCH-R for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis.
  Clinical lymphoma, myeloma & leukemia 2022 Othman T, Penaloza J, Zhang S, Daniel CE, Gaut D, Oliai C, Brem EA, Baweja A, Ly J, Reid J, Pinter-Brown L, Lee M, Abdulhaq H, Tuscano J
• Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham's Lymphangiomatosis: Review of the Literature.
  Case reports in hematology 2022 Lee M, Martin BA, Abdulhaq H
• Clinicopathological characteristics of high-risk multiple myeloma in Hispanic versus non-Hispanic patients in central California
  Journal of Clinical Oncology 2022 Andrew Hwang, Jason Doornenbal, Daniel Park, Inderpreet Bal, Mohammed SANI Bukari, Yueqi Yan, Haifaa Abdulhaq
• Clinicopathological characteristics of high-risk multiple myeloma in Hispanic versus non-Hispanic patients in central California.
  Journal of Clinical Oncology 2022 Andrew Hwang, Jason Doornenbal, Daniel Park, Inderpreet Bal, Mohammed SANI Bukari, Yueqi Yan, Haifaa Abdulhaq
• Clinicopathologic Characteristic and Natural History of Patients with Non Hereditary, Non Polycythemia Vera (NH/NPV) Persistent Polycythemia.
  Blood 2021 Omar Mahmood, Hanson Mouanoutoua, Tanjot Saini, Marcel Okura, Mahboub Rahman Noori, Nadia Almasri, Haifaa Abdulhaq, Sani Bukari
• Ethnic Variation in Hospitalized COVID-19 Patients and Correlation with Coagulopathy, Thrombosis, Prognosis and 30 Day Mortality Outcomes in California's Central Valley.
  Blood 2021 Charity A Huang, Omar Mahmood, Paul Mills, Mehdia Amini, Sundeep Bekal, Jason Doornenbal, Sani Bukari, Yabby Abejie, Haifaa Abdulhaq
• Evaluation of Pulmonary Toxicities in Lymphoma Patients Receiving Brentuximab Vedotin.
  Blood 2021 Tiffany Guan, Mimi Lo, Rebecca Young, Fouad Boulbol, Hanson Mouanoutoua, Raymond Chu, Weiyun Z. Ai, Haifaa Abdulhaq, Bita Fakhri
• First-Line Treatment with R-CHOP Vs Dose-Adjusted R-EPOCH for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis.
  Blood 2021 Tamer Othman, Juan Penaloza, Elizabeth A Brem, Lauren C. Pinter-Brown, Abinav Baweja, Matthew Hyun Joon Lee, Jane Ly, Jack Reid, Haifaa Abdulhaq, Daria Gaut, Caspian Oliai, Erin G. Reid, Joseph M …
• OCEAN (OP-103): Melflufen/Dexamethasone (Dex) Compared with Pomalidomide (Pom)/Dex in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Safety and Tolerability Analyses.
  Blood 2021 Paul G. Richardson, Fredrik H. Schjesvold, Haifaa Abdulhaq, Daniel Coriu, Antonio Lazzaro, Pieter Sonneveld, Torbjörn Kullenburg, Johan Harmenberg, Marcus Thuresson, Catriona Byrne, María-Victoria …
• Diversity of genetic alterations of primary central nervous system lymphoma in Hispanic versus non-Hispanic patients.
  Cancer treatment and research communications 2021 Barakat M, Albitar M, Whitney R, Abdulhaq H
• Efficacy of Venetoclax and Dexamethasone in Refractory IgM Primary Plasma Cell Leukemia with t(11;14) and TP53 Mutation: A Case Report and Literature Review.
  Case reports in hematology 2020 Valliani S, Ali M, Mahmoo O, Hinduja S, Chen CK, Damon L, Abdulhaq H
• Using Targeted RNA Next Generation Sequencing and Differential Expression to Compare Primary Central Nervous System Lymphoma with CD+ DLBCL, Nodal DLBCL and EBV+ DLBCL.
  Blood 2020 Haifaa Abdulhaq, Maher Albitar
• Clinicopathological Features of Double-Hit and Double-Expressor Lymphomas in Hispanics Versus Non-Hispanics in Central California
  Clinicopathological Features of Double-Hit and Double-Expressor Lymphomas in Hispanics Versus Non-Hispanics in Central California 2020 MatthewLee,TannerMortenson,MahboubNoori,DianaMoers,Mohammed Bukari, HaifaaAbdulhaq
• ABCL-078: Clinicopathological Features of Double-Hit and Double-Expressor Lymphomas in Hispanics Versus Non-Hispanics in Central California.
  Clinical Lymphoma Myeloma & Leukemia 2020 Matthew Lee, Tanner Mortenson, Mahboub Noori, Diana Moers, Mohammed Bukari, Haifaa Abdulhaq
• ABCL-407: Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Sirolimus-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham's Lymphangiomatosis: A Case Report.
  Clinical Lymphoma Myeloma & Leukemia 2020 Matthew Lee, Beth Martin, Haifaa Abdulhaq
• Positive Response to Fluorouracil and Oxaliplatin in Signet Ring Cell Adenocarcinoma of the Bladder Presenting With Retroperitoneal Fibrosis.
  Cureus 2020 Hinduja S, Abdulhaq H, Valliani S, Ali MM
• Clinicopathologic and molecular profile of Philadelphia like ALL in Hispanic population of Central Valley California.
  Journal of Clinical Oncology 2020 Hugo Akabane, Mir Ali, Haifaa Abdulhaq, Mohammed SANI Bukari
• Clinicopathologic profile of extramedullary plasmacytoma in Central Valley.
  Journal of Clinical Oncology 2020 Salimah Valliani, Mohamad Barakat, Harinder Gill, Jerome Okudo, Haifaa Abdulhaq, Mohammed SANI Bukari
• Leukemic infiltration in the settings of acute respiratory failure.
  Oxford medical case reports 2019 Fayed M, Evans T, Abdulhaq H
• Diversity of genetic alterations of primary central nervous system lymphoma in Hispanic versus non-Hispanic population.
  Journal of Clinical Oncology 2019 Mohamad Barakat, Maher Albitar, Robin L. Whitney, Calvin Chen, Yu-Hung Kuo, William Silveira, Mohammed SANI Bukari, Subramanyeswara Rao Arekapudi, Karamjit Dhaliwal-Binning, Haifaa Abdulhaq
• Molecular profiling of primary central nervous system lymphoma as compared to activated B-cell subtype of diffuse large B-cell lymphoma.
  Journal of Clinical Oncology 2019 Mohamad Barakat, Maher Albitar, Zijun Xu-Monette, Ken H Young, Haifaa Abdulhaq
• Potential of Germline CDKN2A I49T as a Targetable Driver Mutation: Prolonged Control of Refractory Osteosarcoma with CDK4/6 Inhibitor in a Familial Cancer.
  Journal of Carcinogenesis & Mutagenesis 2019 Omid S Tehrani, Haifaa Abdulhaq, Celia D Delozier
• Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant.
  Case reports in hematology 2018 Rahmat LT, Nguyen A, Abdulhaq H, Prakash S, Logan AC, Mannis GN
• A rare case of rosai-dorfman disease in an adult male associated with auto-immune hemolytic anemia.
  Mediterranean journal of hematology and infectious diseases 2013 Sachdeva M, Abdulhaq H
• Zosteriform Rash as the First Sign of Metastatic Non-small Cell Carcinoma of the Lung (A Case Report.
  CHEST Journal 2011 Mostafa Tabassomi, Haifaa Abdulhaq, Eyad Almasri, Nastran Hashemi
• Viability and potency of hematopoietic progenitor cells after prolonged cryopreservation at -80°C.
  Acta haematologica 2011 Costa R, Khattab M, Gilmore GL, Sahovic EA, Miller SM, Rossetti JM, Abdulhaq H, Lister J
• Activity of azacitidine in chronic myelomonocytic leukemia.
  Cancer 2010 Costa R, Abdulhaq H, Haq B, Shadduck RK, Latsko J, Zenati M, Atem FD, Rossetti JM, Sahovic EA, Lister J
• Viability And Potency Of Hematopoietic Progenitor Cells After Prolonged Cryopreservation At -80 °C.
  Biology of Blood and Marrow Transplantation 2010 M. Khattab, G.L. Gilmore, E.A. Sahovic, S.M. Miller, J.M. Rossetti, H. Abdulhaq, J. Lister
• Azacitidine in the Treatment of Elderly Patients with Acute Myelogenous Leukemia.
  Blood 2009 Heather L. Benjamin, James M. Rossetti, Aaron J. Lampkin, Christie Hilton, Entezam Sahovic, Haifaa Abdulhaq, Richard K. Shadduck, Namratha Vemulapalli, Amanda Hercules, John Lister
• Safety of adjuvant endocrine therapy in postmenopausal women with breast cancer.
  American journal of clinical oncology 2008 Abdulhaq H, Geyer C
• Activity of Azacitidine (AZA) in Chronic Myelomonocytic Leukemeia (CMML).
  Blood 2008 Haifaa Abdulhaq, Bushra Haq, James M. Rossetti, Richard K. Shadduck, Entezam Sahovic, Dijana Christianson, John Lister
• Azacitidine in the Treatment of Elderly Patients with Acute Myelogenous Leukemia.
  Blood 2008 George Labban, James M. Rossetti, Richard K. Shadduck, Entezam Sahovic, Haifaa Abdulhaq, Jean Goy, Lisa Wilt, Rich Wonder, John Lister
• The role of azacitidine in the treatment of myelodysplastic syndromes.
  Expert opinion on investigational drugs 2007 Abdulhaq H, Rossetti JM
• Erythroid variant of chronic myelogenous leukemia.
  Leukemia 2007 Talreja N, Abdulhaq H, Shadduck RK, Rossetti J, Jalil A, Makary A, Lister J
• Recent advances in myelodysplastic syndromes.
  Experimental hematology 2007 Shadduck RK, Latsko JM, Rossetti JM, Haq B, Abdulhaq H
• Response to azacitidine (AZA) in patients with secondary myelodysplastic syndrome.
  Journal of Clinical Oncology 2006 H. Abdulhaq, B. Haq, J. Rossetti, J. Lister, R. Shadduck